E
Eric Yvon
Researcher at George Washington University
Publications - 70
Citations - 7609
Eric Yvon is an academic researcher from George Washington University. The author has contributed to research in topics: Immune system & Cytotoxic T cell. The author has an hindex of 30, co-authored 68 publications receiving 6892 citations. Previous affiliations of Eric Yvon include University of Texas MD Anderson Cancer Center & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Third-party umbilical cord blood–derived regulatory T cells prevent xenogenic graft-versus-host disease
Simrit Parmar,Xiaoying Liu,Shawndeep Tung,Simon N. Robinson,Gabriel Rodriguez,Laurence J.N. Cooper,Hui Yang,Nina Shah,Hong Yang,Marina Konopleva,Jeffery J. Molldrem,Guillermo Garcia-Manero,Amer Najjar,Eric Yvon,Ian K. McNiece,Katy Rezvani,Barbara Savoldo,Catherine M. Bollard,Elizabeth J. Shpall +18 more
TL;DR: A new approach to expand Treg from CB is reported and it is shown that prophylactic injection of third-party, CB-derived, ex vivo-expanded Treg led to the prevention of GvHD that translated into improved Gv HD score, decreased circulating inflammatory cytokines and significantly superior overall survival.
Journal ArticleDOI
Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin.
Heidi V. Russell,Douglas Strother,Douglas Strother,Zhuyong Mei,Donna Rill,Edwina J. Popek,Ettore Biagi,Ettore Biagi,Eric Yvon,Malcolm K. Brenner,Raphael Rousseau +10 more
TL;DR: Autologous tumor cell vaccines combining transgenic lymphotactin with IL-2 seem to have little toxicity in humans and can induce an antitumor immune response in this setting, where the immune response was insufficient to overcome active recurrent neuroblastoma.
Journal ArticleDOI
Engineering the TGFβ receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma
Rachel A. Burga,Eric Yvon,Elizabeth Chorvinsky,Rohan Fernandes,C. Russell Cruz,Catherine M. Bollard +5 more
TL;DR: The results support the development of “off-the-shelf” gene-modified NK cells, that overcome TGFβ-mediated immune evasion, in patients with neuroblastoma and other TGF β-secreting malignancies.
Journal ArticleDOI
Prevention of bone marrow and cardiac graft rejection in an H-2 haplotype disparate mouse combination by an anti-LFA-1 antibody.
Marina Cavazzana-Calvo,Sabine Sarnacki,Elie Haddad,De Coene C,Calise D,Eric Yvon,Nadine Cerf-Bensussan,A Fischer +7 more
TL;DR: Results indicate that a nondepleting anti-LFA-1 antibody can efficiently protect against rejection of MHC-incompatible heart and bone marrow and was associated with the induction of T cell tolerance toward donor antigens after bone marrow transplantation.
Journal ArticleDOI
A robust, good manufacturing practice–compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy
Abdullah Alsuliman,Stanley H. Appel,David R. Beers,Rafet Basar,Hila Shaim,Indresh Kaur,Jane Zulovich,Eric Yvon,Muharrem Muftuoglu,Nobuhiko Imahashi,Kayo Kondo,Enli Liu,Elizabeth J. Shpall,Katayoun Rezvani +13 more
TL;DR: In this study, a robust, Good Manufacturing Practice (GMP)-compliant procedure to enrich and expand Tregs from ALS patients are developed and data facilitate and support the implementation of clinical trials of adoptive therapy with ex vivo expanded and highly suppressive T Regs in patients with ALS.